High dose corticosteroids pulse versus standard of care in severe COVID19 pneumonia: A randomized, open label, multicentre, controlled trial.

Post Graduate Institute of Medical Sciences PGIMS Rohtak0 个研究点目标入组 0 人开始时间: 待定最近更新: 2021年11月24日

试验速览

暂无简介。

•COVID19 confirmed case (with nasal or oral swab RT-PCR or rapid antigen positive).
•Chest radiograph suggestive of pneumonia.
•Severity scale according to WHO ordinal scale score of either 4 or 5 or 6 (oxygen requirement or HFNC requirement or NIV requirement or invasive mechanical ventilation).
•Able to and willing to provide informed consent.

•Patients belonging to category 7 (requiring ECMO or vasopressor support).
•Pregnant subjects.
•Patients participating in other clinical trials.
•Known case of any psychiatric illness.
•Treating physician assessed high likelihood of mortality in 72 hours of randomization.
•Subjects who have received steroids dose of over 0.4 mg/kg/day of dexamethasone or 2mg/kg/day of methylprednisolone for over 2 day in past 14 days.
•Co-existing condition mandating the use of high dose steroids.
•Life threatening comorbidities like
•a.CKD requiring dialysis.
•b.Life threatening new onset arrythmia.
•c.Hypotension.
•d.Evidence or suspicion of active bacterial infection.
•e.Evidence or suspicion of acute onset renal or liver failure
•f.Child C category of chronic liver disease.
•g.Co-existing autoimmune disease requiring immunosuppressive drugs.
•h.Concurrent use of tocilizumab/baricitinib/itolizumab.

发起方

Post Graduate Institute of Medical Sciences PGIMS Rohtak